PURPOSE: Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor-A (VEGF-A), has clinical activity in multiple tumor types. We conducted a phase II trial to assess the activity and tolerability of single-agent bevacizumab in recurrent or persistent endometrial cancer (EMC). PATIENTS AND METHODS: Eligible patients had persistent or recurrent EMC after receiving one to two prior cytotoxic regimens, measurable disease, and Gynecologic Oncology Group performance status of
Journal article
Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study
Journal of clinical oncology, Vol.29(16), pp.2259-2265
06/01/2011
DOI: 10.1200/JCO.2010.32.6397
PMCID: PMC3107744
PMID: 21537039
Abstract
Details
- Title: Subtitle
- Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study
- Creators
- Carol AghajanianMichael W SillKathleen M. DarcyBenjamin GreerD Scott McMeekinPeter G RoseJacob RotmenschMack N BarnesParviz HanjaniKimberly K. Leslie - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Journal of clinical oncology, Vol.29(16), pp.2259-2265
- DOI
- 10.1200/JCO.2010.32.6397
- PMID
- 21537039
- PMCID
- PMC3107744
- NLM abbreviation
- J Clin Oncol
- ISSN
- 1527-7755
- Comment
Supported by the Cory Beach Family Fund for Endometrial Cancer Research (K.K.L.) and National Cancer Institute Grant No. U10CA27469 to the Gynecologic Oncology Group (GOG) Administrative Office, Tissue Bank, and Receptor Core; Grant No. U24CA114793 to the GOG Tissue Bank; Grant No. U10CA37517 to the GOG Statistical and Data Center; and Grant No. R01CA99908 (K.K.L.).
Presented in part at the 45th Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2009, Orlando, FL.
- Language
- English
- Date published
- 06/01/2011
- Academic Unit
- Obstetrics and Gynecology
- Record Identifier
- 9983557795502771
Metrics
36 Record Views